Baldwin Wealth Partners LLC MA Decreases Stock Position in Axsome Therapeutics, Inc. $AXSM

Baldwin Wealth Partners LLC MA lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 2.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 48,570 shares of the company’s stock after selling 1,000 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Axsome Therapeutics were worth $5,070,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BVF Inc. IL lifted its position in shares of Axsome Therapeutics by 21.8% in the first quarter. BVF Inc. IL now owns 1,690,221 shares of the company’s stock valued at $197,130,000 after acquiring an additional 302,157 shares in the last quarter. Invesco Ltd. lifted its position in shares of Axsome Therapeutics by 23.8% in the first quarter. Invesco Ltd. now owns 857,001 shares of the company’s stock valued at $99,952,000 after acquiring an additional 164,537 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Axsome Therapeutics by 4.5% in the first quarter. Wellington Management Group LLP now owns 703,279 shares of the company’s stock valued at $82,023,000 after acquiring an additional 30,122 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Axsome Therapeutics by 16,852.7% in the first quarter. Assenagon Asset Management S.A. now owns 627,418 shares of the company’s stock valued at $73,176,000 after acquiring an additional 623,717 shares in the last quarter. Finally, Nuveen LLC purchased a new position in shares of Axsome Therapeutics in the first quarter valued at approximately $48,185,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the firm’s stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $115.96, for a total transaction of $1,159,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark Coleman bought 1,575 shares of the business’s stock in a transaction on Monday, September 8th. The shares were acquired at an average cost of $127.28 per share, with a total value of $200,466.00. Following the purchase, the director owned 48,212 shares of the company’s stock, valued at $6,136,423.36. The trade was a 3.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 243,332 shares of company stock worth $28,824,746 in the last three months. 22.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on AXSM shares. Needham & Company LLC restated a “buy” rating and issued a $150.00 target price on shares of Axsome Therapeutics in a research report on Monday, August 4th. B. Riley assumed coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target for the company. Bank of America increased their price target on Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Royal Bank Of Canada increased their price target on Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $177.93.

Axsome Therapeutics Price Performance

AXSM stock opened at $122.52 on Friday. The business has a fifty day moving average of $116.47 and a two-hundred day moving average of $109.98. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock has a market cap of $6.11 billion, a price-to-earnings ratio of -24.17 and a beta of 0.52. Axsome Therapeutics, Inc. has a 52-week low of $75.56 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.08. The company had revenue of $150.04 million during the quarter, compared to analysts’ expectations of $140.02 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%. As a group, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.